CBZ-D-GLN 谷氨酰胺 | 13139-52-1

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 谷氨酰胺类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: CBZ-D-GLN 谷氨酰胺
• 中文别名: CBZ-D-GLN谷氨酰胺；Z-D-谷氨酰胺；Cbz-D-谷氨酰胺
• 英文名称: N-carbobenzoxy-D-glutamine
• 英文别名: N-benzyloxycarbonyl-D-glutamine；D-Z-Gln-OH；N-CBZ-D-glutamine；Cbz-D-Gln-OH；N(α)-Cbz-D-glutamine；Benzyloxycarbonyl-D-glutamin；(2R)-5-amino-5-oxo-2-(phenylmethoxycarbonylamino)pentanoic acid
• CAS: 13139-52-1
• 化学式: C₁₃H₁₆N₂O₅
• 分子量: 280.28
• InChiKey: JIMLDJNLXLMGLX-SNVBAGLBSA-N

物化性质

• 熔点：
  138-142°C
• 沸点：
  604.2±55.0 °C(Predicted)
• 密度：
  1.316
• 溶解度：
  DMSO（微溶）、甲醇（微溶、超声处理）

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  20
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25
• WGK Germany：
  3
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : Z-D-Gln-OH
CAS-No. : 13139-52-1
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Not a hazardous substance or mixture according to Regulation (EC) No. 1272/2008.
Not a hazardous substance or mixture according to EC-directives 67/548/EEC or 1999/45/EC.
Label elements
Caution - substance not yet tested completely.
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : Z-D-glutamine
Formula : C13H16N2O5
Molecular Weight : 280,28 g/mol

---

Section 4. FIRST AID MEASURES
Description of first aid measures
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration.
In case of skin contact
Wash off with soap and plenty of water.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water.
Most important symptoms and effects, both acute and delayed
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIREFIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Avoid dust formation. Avoid breathing vapors, mist or gas.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Sweep up and shovel. Keep in suitable, closed containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
General industrial hygiene practice.
Personal protective equipment
Eye/face protection
Use equipment for eye protection tested and approved under appropriate government standards
such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Choose body protection in relation to its type, to the concentration and amount of dangerous
substances, and to the specific work-place., The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Respiratory protection is not required. Where protection from nuisance levels of dusts are desired,
use type N95 (US) or type P1 (EN 143) dust masks. Use respirators and components tested and
approved under appropriate government standards such as NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: powder
Colour: white
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density no data available
n) Water solubility no data available
o) Partition coefficient: n- no data available
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
no data available
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
no data available
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation
May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion May be harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes May cause eye irritation.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

Section 15. REGULATORY INFORMATION
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
no data available
Chemical Safety Assessment
no data available

---

Section 16. OTHER INFORMATION
Further information
Copyright 2012 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  CBZ-D-GLN 谷氨酰胺 在 氯化铵 、 三乙胺 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 1.0h， 生成 Cbz-D-Gln-NH₂
  参考文献：
  名称：

  在温和条件下通过氯甲酸乙酯和三乙胺活化羧酸方便地制备伯酰胺

  摘要：

  通过用 ClCO2Et 和 Et3N 活化，用 NH4Cl 从相应的羧酸 1 或 5 中很容易以 22-99% 的产率制备伯酰胺。相应伯胺的对映体...

  DOI：

  10.1246/cl.130096
• 作为产物：
  描述：

  2-benzyloxycarbonylamino-4-carbamoyl-butyric acid ethyl ester 以89%的产率得到
  参考文献：
  名称：

  MORINIERE, J. L.;DANREE, B.;LEMOINE, J.;GUY, A., SYNTH. COMMUN., 18,(1988) N 4, 441-444

  摘要：

  DOI：

文献信息

• [EN] NEW HETEROCYCLIC AMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] NOUVEAUX COMPOSES AMIDES HETEROCYCLIQUES UTILISES POUR LE TRAITEMENT D'AFFECTIONS INFLAMMATOIRES ET ALLERGIQUES; PROCEDE PERMETTANT DE LES FABRIQUER ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLENMARK PHARMACEUTICALS LTD

  公开号：WO2004022536A1

  公开（公告）日：2004-03-18

  The present invention relates to novel heterocyclic compounds that inhibit phosphodiesterase type 4 (PDE 4). The compounds are useful for treating inflammatory conditions, diseases of the central nervous systems and insulin resistant diabetes.

  本发明涉及一种新型杂环化合物，可抑制磷酸二酯酶4型（PDE 4）。这些化合物可用于治疗炎症性疾病、中枢神经系统疾病和胰岛素抵抗性糖尿病。
• Aminoacid derivatives of cephalosporin compounds
  申请人：——

  公开号：US04311698A1

  公开（公告）日：1982-01-19

  Novel organic amide compounds which are N-[6-[(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinyl]cephalosporin compounds having broad spectrum antibacterial utility are provided by (a) reacting the free amino acid of the appropriate cephalosporin or the acid salt or silylated derivative or complex thereof with a reactive derivative of the corresponding N-6-[(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinic acid or (b) reacting the free amino acid 7-aminocephalosporanic acid or a related compound or the acid salt or silylated derivative thereof with a reactive derivative of the corresponding D-N-[6-(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinyl]-2-substituted glycine. Pharmaceutical compositions containing said compounds and methods for treating infections using said compositions are also disclosed.

  本发明提供了一种具有广谱抗菌效用的N-[6-[(acylaminoacylamino或aminoacylamino)苯基]-1,2-二氢-2-氧基喹啉酰头孢菌素化合物的新型有机酰胺化合物，其方法包括：(a)将适当头孢菌素的游离氨基酸或其酸盐或硅烷衍生物或其复合物与相应的N-6-[(acylaminoacylamino或aminoacylamino)苯基]-1,2-二氢-2-氧基喹啉酸的反应性衍生物反应；或者(b)将游离氨基酸7-氨基头孢菌烷酸或相关化合物或其酸盐或硅烷衍生物与相应的D-N-[6-(acylaminoacylamino或aminoacylamino)苯基]-1,2-二氢-2-氧基喹啉酰基]-2-取代甘氨酸的反应性衍生物反应。本发明还揭示了含有该化合物的制药组合物以及使用该组合物治疗感染的方法。
• ANTIBACTERIAL AMIDE-MACROCYCLES V
  申请人：ENDERMANN Rainer

  公开号：US20080275018A1

  公开（公告）日：2008-11-06

  The invention relates to antibacterial amide-macrocycles of formula (I), in which R 26 represents hydrogen, halogen, amino or methyl, R 7 represents a group of formula (II), (III), (IV) or (V), whereby R 1 represents hydrogen or hydroxy and * is the linkage site to the carbon atom, R 2 represents hydrogen or methyl and methods for their production, their use for the treatment and/or prophylaxis of diseases as well as their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular of bacterial infections.

  本发明涉及式（I）的抗菌酰胺大环化合物，其中R26代表氢、卤素、氨基或甲基，R7代表式（II）、（III）、（IV）或（V）的基团，其中R1代表氢或羟基，*是连接到碳原子的连接位点，R2代表氢或甲基，以及它们的制备方法，它们用于治疗和/或预防疾病的用途，以及它们用于制备治疗和/或预防疾病的药物，特别是用于治疗细菌感染。
• Compounds and Methods for Inhibiting Axillary Malodour
  申请人：Natsch Andreas

  公开号：US20110318290A1

  公开（公告）日：2011-12-29

  Enzymes mediating in the release of compounds characteristic of human malodour and in particular axillary malodour, and compounds that inhibit said enzymes having the general formula (I)

  催化释放人类恶臭特征化合物，特别是腋臭的酶，以及具有一般式（I）的抑制该酶的化合物。
• N-(6-((acylaminoacylamino or aminoacylamino)phenyl)-1,2-dihydro-2-oxonicotinyl) cephalosporin compounds, processes for their production, and compositions containing the same
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP0015771A1

  公开（公告）日：1980-09-17

  N-[6-[(acylaminoacylamino or aminoacylamino) phenyl]-1,2-dihydro-2-oxonicotinyl] cephalosporin compounds having the formula: wlth broad spectrum antibacterial utility are provided, which can be produced by (a) reacting the free amino acid of the appropriate cephalosporin or the acid salt or silylated derivative or complex thereof with a reactive derivative of the corresponding N-6-[(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinic acid, or (b) reacting the free amino acid 7-aminocephalosporanic acid or a related compound or the acid salt or silylated derivative thereof with a reactive derivative of the corresponding D-N-[6-[(acylaminoacylamino or aminoacylamino)phenyl]-1,2-dihydro-2-oxonicotinyl]-2-substituted glycine. Pharmaceutical compositions containing the novel compounds and methods for treating infections using such compositions are also disclosed.

  提供了 N-[6-[(酰氨基乙酰氨基或氨基乙酰氨基)苯基]-1,2-二氢-2-氧代烟酸基]头孢菌素化合物，其化学式如下： 提供了具有广谱抗菌效用的头孢菌素化合物，该化合物可通过 (a) 将相应头孢菌素的游离氨基酸或其酸盐或硅烷化衍生物或络合物与相应的 N-6-[(酰氨基乙酰氨基或氨基乙酰氨基)苯基]-1.N-6-[(酰氨基乙酰氨基或氨基乙酰氨基)苯基]-2-二氢-2-氧代烟酸酯的活性衍生物反应而制得，该化合物具有以下式子或 (b) 将游离氨基酸 7-氨基头孢烷酸或其相关化合物或其酸盐或硅烷基化衍生物与相应的 D-N-[6-[（酰氨基乙酰氨基或氨基乙酰氨基）苯基]-1,2-二氢-2-氧代烟酸基]-2-取代甘氨酸的活性衍生物反应。此外，还公开了含有新型化合物的药物组合物以及使用此类组合物治疗感染的方法。